Marshall Devor

Prof. Marshall Devor

Institute of Life Sciences, The Hebrew University of Jeusalem, West Jerusalem, Israel
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
Marshall DevorMarshall Devor
Marshall Devor
RARon Amir
Ron Amir
ZRZ. Harry Rappaport
Z. Harry Rappaport
There are no satisfactory animal models of trigeminal neuralgia, and it is difficult to obtain essential data from patients. However, trigeminal neuralgia presents with such idiosyncratic signs and symptoms, and responds to so distinctive a set of therapeutic modalities, that scientific deduction can be used to generate likely hypotheses. The ignition hypothesis of trigeminal neuralgia is based on recent advances in the understanding of abnormal electrical behavior in injured sensory neurons, and new histopathologic observations of biopsy specimens from patients with trigeminal neuralgia who are undergoing microvascular decompression surgery. According to the hypothesis, trigeminal neuralgia results from specific abnormalities of trigeminal afferent neurons in the trigeminal root or ganglion. Injury renders axons and axotomized somata hyperexcitable. The hyperexcitable afferents, in turn, give rise to pain paroxysms as a result of synchronized afterdischarge activity. The ignition hypothesis accounts for the major positive and negative signs and symptoms of trigeminal neuralgia, for its pathogenesis, and for the efficacy of treatment modalities. Proof, however, awaits the availability of key experimental data that can only be obtained from patients with trigeminal neuralgia.

26 February 2009 in Experimental Brain Research
Verified
Journal Article
Closed access
PDF file
Marshall DevorMarshall Devor
Marshall Devor

1 January 2006 in The Journal of Pain
Verified
Journal Article
Closed access
Marshall DevorMarshall Devor
Marshall Devor

1 July 2014 in Pain
Verified
Journal Article
Closed access
AVApostol Vaso
Apostol Vaso
HAHaim-Moshe Adahan
Haim-Moshe Adahan
AGArtan Gjika
Artan Gjika
SZSkerdi Zahaj
Skerdi Zahaj
TZTefik Zhurda
Tefik Zhurda
Marshall DevorMarshall Devor
Marshall Devor
Nearly all amputees continue to feel their missing limb as if it still existed, and many experience chronic phantom limb pain (PLP). What is the origin of these sensations? There is currently a broad consensus among investigators that PLP is a top-down phenomenon, triggered by loss of sensory input and caused by maladaptive cortical plasticity. We tested the alternative hypothesis that PLP is primarily a bottom-up process, due not to the loss of input but rather to exaggerated input, generated ectopically in axotomized primary afferent neurons in the dorsal root ganglia (DRGs) that used to innervate the limb. In 31 amputees, the local anesthetic lidocaine was applied intrathecally and/or to the DRG surface (intraforaminal epidural block). This rapidly and reversibly extinguished PLP and also nonpainful phantom limb sensation (npPLS). Control injections were ineffective. For intraforaminal block, the effect was topographically appropriate. The suppression of PLP and npPLS could also be demonstrated using dilute lidocaine concentrations that are sufficient to suppress DRG ectopia but not to block the propagation of impulses generated further distally in the nerve. PLP is driven primarily by activity generated within the DRG. We recommend the DRG as a target for treatment of PLP and perhaps also other types of regional neuropathic pain.

1 March 2002 in Journal of Neurosurgery
Verified
Journal Article
Closed access
Marshall DevorMarshall Devor
Marshall Devor
RGRuth Govrin-Lippmann
Ruth Govrin-Lippmann
ZRZ. Harry Rappaport
Z. Harry Rappaport
Object. Recent progress in the understanding of abnormal electrical behavior in injured sensory neurons motivated an examination, at the ultrastructural level, of trigeminal roots of patients with trigeminal neuralgia (TN). Methods. In 12 patients biopsy specimens of trigeminal root were obtained during surgery for microvascular decompression. Pathological changes in tissue included axonopathy and axonal loss, demyelination, a range of less severe myelin abnormalities (dysmyelination), residual myelin debris, and the presence of excess collagen, including condensed collagen masses in two cases. Within zones of demyelination, groups of axons were often closely apposed without an intervening glial process. Pathological characteristics of nerve fibers were clearly graded with the degrees of root compression noted at operation. Pain also occurred, however, in some patients who did not appear to have a severe compressive injury. Conclusions. Findings were consistent with the ignition hypothesis of TN. This model can be used to explain the major positive and negative symptoms of TN by axonopathy-induced changes in the electrical excitability of afferent axons in the trigeminal root and of neuronal somata in the trigeminal ganglion. The key pathophysiological changes include ectopic impulse discharge, spontaneous and triggered afterdischarge, and crossexcitation among neighboring afferents.

27 April 2015 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LVLucas Vicuña
Lucas Vicuña
DSDavid E Strochlic
David E Strochlic
ALAlban Latremoliere
Alban Latremoliere
KBKiran Kumar Bali
Kiran Kumar Bali
MSManuela Simonetti
Manuela Simonetti
Rohini KunerRohini Kuner
Rohini Kuner
Inhibition of T cell–derived leukocyte elastase by neuronal SerpinA3N or the drug Sivelestat reduces neuropathic pain. Neuropathic pain is a major, intractable clinical problem and its pathophysiology is not well understood. Although recent gene expression profiling studies have enabled the identification of novel targets for pain therapy1,2,3,4, classical study designs provide unclear results owing to the differential expression of hundreds of genes across sham and nerve-injured groups, which can be difficult to validate, particularly with respect to the specificity of pain modulation5. To circumvent this, we used two outbred lines of rats6, which are genetically similar except for being genetically segregated as a result of selective breeding for differences in neuropathic pain hypersensitivity7. SerpinA3N, a serine protease inhibitor, was upregulated in the dorsal root ganglia (DRG) after nerve injury, which was further validated for its mouse homolog. Mice lacking SerpinA3N developed more neuropathic mechanical allodynia than wild-type (WT) mice, and exogenous delivery of SerpinA3N attenuated mechanical allodynia in WT mice. T lymphocytes infiltrate the DRG after nerve injury and release leukocyte elastase (LE), which was inhibited by SerpinA3N derived from DRG neurons. Genetic loss of LE or exogenous application of a LE inhibitor (Sivelastat) in WT mice attenuated neuropathic mechanical allodynia. Overall, we reveal a novel and clinically relevant role for a member of the serpin superfamily and a leukocyte elastase and crosstalk between neurons and T cells in the modulation of neuropathic pain.